The NIH-led trial will assess 3 drugs: infliximab, a tumor necrosis factor blocker, abatacept, a selective T cell costimulation modulator, and cenicriviroc, an investigational immunomodulator that blocks 2 chemokine receptors, CCR2 and CCR5.
The antibody solution is derived from plasma donated by healthy individuals who have recovered from COVID-19.
The FDA has issued recommendations regarding the issuance of emergency use authorization for investigational COVID-19 vaccines.
The FDA has approved Simponi Aria for the treatment of patients aged 2 years and older with active polyarticular juvenile idiopathic arthritis.
A phase 3 trial evaluating the vaccine candidate, JNJ-78436735 (Ad26.COV2.S; Janssen), for the prevention of COVID-19 has been initiated.
Patients treated with tofacitinib experienced significantly fewer disease flares compared with placebo.
The FDA has issued an Emergency Use Authorization (EUA) for Assure COVID-19 IgG/IgM Rapid Test Device.
Both randomized, placebo-controlled trials are expected to enroll approximately 1000 hospitalized patients.
Patients treated with tocilizumab were 44% less likely to progress to mechanical ventilation or death compared with placebo.
Avacopan is an orally-administered, small molecule designed to selectively block the complement 5a receptor on destructive inflammatory cells such as blood neutrophils.
